Figure 2
From: Efficacy of SPI-1865, a novel gamma-secretase modulator, in multiple rodent models
In vitro pharmacology of SPI-1865, a unique gamma-secretase modulator that lowers β-amyloid (Aβ) 42 and Aβ 38 . CHO-2B7 cells were treated with increasing concentrations of SPI-1865. Conditioned media were collected after 5 hrs of treatment and the levels of Aβ peptides were assessed. The values for each Aβ38, Aβ40 and Aβ42 for each of the doses are expressed as a percentage of the Aβ levels from vehicle-treated cells. IC50's of Aβ38 (259 nM), Aβ42 (106 nM) and Aβ40 (2.8 μM) were calculated by using the inflection point or extrapolated from the curve at Aβxx 50% lowering, as appropriate. The listed values were averaged from multiple experiments and a representative dose response is shown here.